Ser675
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser675  -  CTNNB1 (human)

Site Information
QDykKRLsVELtsSL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 457120

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 56 ) , immunoprecipitation ( 2 , 4 , 11 , 31 , 55 ) , mass spectrometry ( 1 , 3 , 8 , 9 , 10 , 13 , 14 , 15 , 16 , 17 , 19 , 20 , 21 , 23 , 24 , 26 , 27 , 28 , 29 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 58 ) , mutation of modification site ( 5 , 11 , 31 , 55 , 56 ) , phospho-antibody ( 2 , 4 , 5 , 7 , 11 , 12 , 32 , 40 , 46 , 55 , 57 ) , western blotting ( 2 , 4 , 5 , 7 , 11 , 31 , 32 , 40 , 46 , 55 )
Disease tissue studied:
bone cancer ( 12 ) , breast cancer ( 5 , 8 , 14 , 15 , 23 ) , breast ductal carcinoma ( 14 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 , 14 ) , cervical cancer ( 45 ) , cervical adenocarcinoma ( 45 ) , colorectal cancer ( 46 ) , colorectal carcinoma ( 46 ) , gastric cancer ( 47 , 48 ) , kidney cancer ( 40 ) , hepatocellular carcinoma, surrounding tissue ( 41 ) , lung cancer ( 13 , 23 , 26 , 27 , 28 , 29 ) , non-small cell lung cancer ( 23 , 26 , 27 , 28 , 29 ) , non-small cell lung adenocarcinoma ( 13 ) , non-small cell squamous cell lung carcinoma, surrounding tissue ( 52 ) , ovarian cancer ( 7 , 14 ) , pancreatic ductal adenocarcinoma ( 19 ) , prostate cancer ( 12 ) , melanoma skin cancer ( 10 )
Relevant cell line - cell type - tissue:
'brain, cerebral cortex' ( 38 ) , 'muscle, skeletal' ( 33 ) , 'pancreatic, ductal'-pancreas ( 19 ) , 293 (epithelial) ( 2 , 31 , 50 , 56 , 57 ) , 293 (epithelial) [AT1 (human), transfection] ( 39 ) , 293T (epithelial) ( 55 ) , 786-O (renal) ( 9 ) , 786-O (renal) [VHL (human), transfection] ( 9 ) , A431 (epithelial) ( 55 , 58 ) , A498 (renal) [SFRP2 (human), transfection] ( 40 ) , A549 (pulmonary) ( 20 ) , breast ( 3 , 14 ) , BT-20 (breast cell) ( 23 ) , BT-474 (breast cell) ( 8 ) , BT-549 (breast cell) ( 23 ) , Calu 6 (pulmonary) ( 23 ) , COS (fibroblast) ( 31 , 54 , 56 ) , Flp-In T-Rex-293 (epithelial) ( 24 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 24 ) , H2009 (pulmonary) ( 23 ) , H2077 (pulmonary) ( 23 ) , H2887 (pulmonary) ( 23 ) , H322 (pulmonary) ( 23 ) , H322M (pulmonary) ( 23 ) , HCC1359 (pulmonary) ( 23 ) , HCC1937 (breast cell) ( 23 ) , HCC2279 (pulmonary) ( 23 ) , HCC366 (pulmonary) ( 23 ) , HCC4006 (pulmonary) ( 23 ) , HCC78 (pulmonary) ( 23 ) , HCC827 (pulmonary) ( 23 ) , HeLa (cervical) ( 1 , 2 , 4 , 34 , 37 , 51 , 53 ) , HeLa S3 (cervical) ( 45 ) , hepatocyte-liver ( 41 ) , HMLER ('stem, breast cancer') ( 15 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 15 ) , HOP62 (pulmonary) ( 23 ) , HUES-7 ('stem, embryonic') ( 49 ) , HUES-9 ('stem, embryonic') ( 36 ) , Jurkat (T lymphocyte) ( 21 , 35 , 42 , 43 , 44 ) , L cells (fibroblast) ( 57 ) , LCLC-103H (pulmonary) ( 23 ) , liver ( 17 ) , LNCaP (prostate cell) ( 12 ) , LOU-NH91 (squamous) ( 23 ) , lung ( 52 ) , MCF-7 (breast cell) ( 5 , 8 , 23 ) , MDA-MB-231 (breast cell) ( 23 ) , MDA-MB-468 (breast cell) ( 23 ) , NCI-H1395 (pulmonary) ( 23 ) , NCI-H1568 (pulmonary) ( 23 ) , NCI-H157 (pulmonary) ( 23 ) , NCI-H1648 (pulmonary) ( 23 ) , NCI-H1650 (pulmonary) ( 26 , 27 , 28 , 29 ) , NCI-H1666 (pulmonary) ( 23 ) , NCI-H2030 (pulmonary) ( 23 ) , NCI-H2172 (pulmonary) ( 23 ) , NCI-H460 (pulmonary) ( 23 ) , NCI-H520 (squamous) ( 23 ) , NCI-H647 (pulmonary) ( 23 ) , NCMiCaSR (endothelial) [CaR (human), genetic knockin] ( 32 ) , ovary ( 14 ) , PC9 (pulmonary) ( 13 , 23 ) , SH-SY5Y (neural crest) ( 16 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 16 ) , SKOV-3 (ovarian) ( 7 ) , stomach ( 47 , 48 ) , SUM159 (breast cell) ( 5 ) , SW480 (intestinal) ( 46 ) , U2OS (bone cell) ( 12 ) , WM239A (epidermal) ( 10 )

Upstream Regulation
Regulatory protein:
ARFGEF1 (human) ( 4 ) , ARFGEF2 (human) ( 4 ) , CaR (human) ( 32 ) , GSKIP (human) ( 2 ) , Merlin (human) ( 5 ) , SFRP2 (human) ( 40 )
Putative in vivo kinases:
PAK1 (human) ( 30 ) , PAK4 (human) ( 12 , 31 ) , PKACA (human) ( 57 )
Kinases, in vitro:
MEKK2 (human) ( 6 ) , PAK4 (human) ( 31 ) , PKACA (human) ( 55 , 56 , 57 )
Treatments:
Ca(2+) ( 32 ) , cAMP_analog ( 57 ) , colforsin ( 56 ) , EGF ( 1 ) , H-89 ( 2 ) , LRRK2-IN-1 ( 16 ) , microparticles ( 7 ) , nocodazole ( 45 ) , NSC23766 ( 7 ) , PKI ( 2 ) , tecalcet ( 32 ) , Wnt ( 2 )

Downstream Regulation
Effects of modification on CTNNB1:
activity, induced ( 56 ) , intracellular localization ( 31 , 46 ) , molecular association, regulation ( 56 ) , protein stabilization ( 30 , 31 , 57 )
Effects of modification on biological processes:
transcription, induced ( 2 , 4 , 30 , 31 , 56 )
Induce interaction with:
p300 (human) ( 56 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Dema A, et al. (2016) The A-Kinase Anchoring Protein (AKAP) Glycogen Synthase Kinase 3β Interaction Protein (GSKIP) Regulates β-Catenin through Its Interactions with Both Protein Kinase A (PKA) and GSK3β. J Biol Chem 291, 19618-30
27484798   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Li CC, et al. (2016) Enhancement of β-catenin activity by BIG1 plus BIG2 via Arf activation and cAMP signals. Proc Natl Acad Sci U S A 113, 5946-51
27162341   Curated Info

5

Morrow KA, et al. (2016) Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget 7, 17991-8005
26908451   Curated Info

6

Greenblatt MB, et al. (2016) MEKK2 mediates an alternative β-catenin pathway that promotes bone formation. Proc Natl Acad Sci U S A 113, E1226-35
26884171   Curated Info

7

Al Thawadi H, et al. (2016) VE-cadherin cleavage by ovarian cancer microparticles induces β-catenin phosphorylation in endothelial cells. Oncotarget 7, 5289-305
26700621   Curated Info

8

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

9

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

10

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

11

Llado V, et al. (2015) Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ Cell Rep
25660024   Curated Info

12

Selamat W, Tay PL, Baskaran Y, Manser E (2015) The Cdc42 Effector Kinase PAK4 Localizes to Cell-Cell Junctions and Contributes to Establishing Cell Polarity. PLoS One 10, e0129634
26068882   Curated Info

13

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

14

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

15

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

16

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

17

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

18

Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113   Curated Info

19

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

20

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

21

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

22

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

23

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

24

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

25

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

26

Possemato A (2012) CST Curation Set: 14060; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

27

Possemato A (2012) CST Curation Set: 14061; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

28

Possemato A (2012) CST Curation Set: 14058; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

29

Possemato A (2012) CST Curation Set: 14059; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

30

Zhu G, et al. (2012) A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells. Oncogene 31, 1001-12
21822311   Curated Info

31

Li Y, et al. (2012) Nucleo-cytoplasmic shuttling of PAK4 modulates β-catenin intracellular translocation and signaling. Biochim Biophys Acta 1823, 465-75
22173096   Curated Info

32

Rey O, et al. (2012) Negative cross-talk between calcium-sensing receptor and β-catenin signaling systems in colonic epithelium. J Biol Chem 287, 1158-67
22094462   Curated Info

33

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

34

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

35

Guo A (2011) CST Curation Set: 11734; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

36

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

37

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

38

Herskowitz JH, et al. (2010) Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration. J Proteome Res 9, 6368-79
20886841   Curated Info

39

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

40

Yamamura S, et al. (2010) Oncogenic functions of secreted Frizzled-related protein 2 in human renal cancer. Mol Cancer Ther 9, 1680-7
20501806   Curated Info

41

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

42

Possemato A (2010) CST Curation Set: 9072; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

43

Possemato A (2010) CST Curation Set: 9073; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

44

Possemato A (2010) CST Curation Set: 9071; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

45

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

46

Maher MT, et al. (2010) Beta-catenin phosphorylated at serine 45 is spatially uncoupled from beta-catenin phosphorylated in the GSK3 domain: implications for signaling. PLoS One 5, e10184
20419129   Curated Info

47

Ren H (2009) CST Curation Set: 8060; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

48

Ren H (2009) CST Curation Set: 8024; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

50

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

51

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

52

Ren H (2008) CST Curation Set: 5491; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

53

Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51
18220336   Curated Info

54

Wang Y, et al. (2007) Profiling signaling polarity in chemotactic cells. Proc Natl Acad Sci U S A 104, 8328-33
17494752   Curated Info

55

Fang D, et al. (2007) Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282, 11221-9
17287208   Curated Info

56

Taurin S, et al. (2006) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281, 9971-6
16476742   Curated Info

57

Hino S, Tanji C, Nakayama KI, Kikuchi A (2005) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol 25, 9063-72
16199882   Curated Info

58

MS This site is one of 509 sites observed by D. Stover et al using MS/FTMS of peptides from lysates of A431 cells grown either in vitro or as xenografts in BALB/c nu/nu mice. These sites were previously unpublished until now (July 27 2006). 66 sites were previously published in: Stover DR, et al. Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts Clin Proteomics 2004 Mar 01; 1(1): 69-80.
Curated Info